Among currently available intravitreal anti-VEGF agents for wet AMD, which agent has been specifically linked to a higher incidence of intraocular inflammation and retinal vasculitis, prompting regulatory warnings and careful post-injection monitoring?
- A Ranibizumab
- B Bevacizumab
- C Brolucizumab ✓
- D Faricimab
Correct answer: C. Brolucizumab
Explanation
Brolucizumab, a single-chain antibody fragment approved for wet AMD, carries a recognised risk of intraocular inflammation including occlusive retinal vasculitis, which led to boxed warnings and recommendations against use in patients with prior ocular inflammatory events. Ranibizumab, bevacizumab, and faricimab have far lower rates of such vasculitic events. This safety distinction is a frequently examined recent addition to ophthalmology pharmacology.
Reference: American Academy of Ophthalmology Basic and Clinical Science Course, Retina Section, 2023 ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.